274263-65-9: Levosimendan Cyanoacetamide Hydrazone Impurity

Status: In-stock

It is an impurity present in Levosimendan, Levosimendan increases myofilament calcium sensitivity by binding to cardiac troponin C in a calcium-dependent manner. by stabilizing the calcium-induced conformational change of troponin C by changing actin-myosin. cross-bridge kinetics apparently without increasing the cycling rate of the cross bridges increasing the effects of calcium on cardiac myofilaments during systole, also have a selective phosphodiesterase (PDE)-III inhibitory action. levosimendan acts preferentially as a Ca2+ sensitizer at lower concentrations whereas at higher concentrations its action as a PDE-III inhibitor becomes more prominent in experimental animals and humans.

Request quotation

Additional information on CAS 274263-65-9

Catalogue No. VE006146
CAS No. 274263-65-9
Molecular Formula C14H14N6O2
Molecular Weight 298.3
Parent drug Levosimendan
IUPAC Name 2-Cyano-2-[[4-[(4R)-1, 4, 5, 6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazono]-acetamide
Synonyms N/A
References Conti, N., Gatti, M., Raschi, E., Diemberger, I., & Potena, L. (2021). Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. Drug Design, Development and Therapy, Volume 15, 3391–3409. https://doi.org/10.2147/dddt.s295214
Status In-stock

Request a quote

We Respond Within a Few Hours - Whether You're a New or Existing Client

Payment Made Simple: All major Credit/Debit cards accepted

Streamlined 3-Step Process from Quotes to Orders:

Product name:

274263-65-9: Levosimendan Cyanoacetamide Hydrazone Impurity

"*" indicates required fields

Products quotation
This field is for validation purposes and should be left unchanged.